tradingkey.logo

Brainsway Ltd

BWAY
15.590USD
0.000
Close 11/07, 16:00ETQuotes delayed by 15 min
589.14MMarket Cap
110.24P/E TTM

Brainsway Ltd

15.590
0.000
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Brainsway Ltd

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Brainsway Ltd's Score

Industry at a Glance

Industry Ranking
96 / 209
Overall Ranking
207 / 4614
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 2 analysts
Buy
Current Rating
18.000
Target Price
+15.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Brainsway Ltd Highlights

StrengthsRisks
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 50.92% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 41.02M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 107.77, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 5.59M shares, decreasing 13.67% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 199.83K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.10.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.49, which is higher than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 12.63M, representing a year-over-year increase of 26.26%, while its net profit experienced a year-over-year increase of 237.83%.

Score

Industry at a Glance

Previous score
9.49
Change
0

Financials

10.00

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data

Quality of Earnings

10.00

Operational Efficiency

10.00

Growth Potential

9.78

Shareholder Returns

7.66

Brainsway Ltd's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 4.12, which is lower than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is 107.77, which is 337.27% below the recent high of 471.25 and 232.77% above the recent low of -143.09.

Score

Industry at a Glance

Previous score
4.12
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 96/209
No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Brainsway Ltd is 18.00, with a high of 19.00 and a low of 17.00.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts
Buy
Current Rating
18.000
Target Price
+15.46%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

89
Total
4
Median
7
Average
Company name
Ratings
Analysts
Brainsway Ltd
BWAY
2
Boston Scientific Corp
BSX
37
Intuitive Surgical Inc
ISRG
35
Edwards Lifesciences Corp
EW
35
Veeva Systems Inc
VEEV
34
Thermo Fisher Scientific Inc
TMO
28
1
2
3
...
18

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 7.22, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 17.49 and the support level at 14.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
7.24
Change
-0.02

Support & Resistance

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.300
Neutral
RSI(14)
43.802
Neutral
STOCH(KDJ)(9,3,3)
17.968
Sell
ATR(14)
0.715
Low Volatility
CCI(14)
-150.119
Sell
Williams %R
82.042
Oversold
TRIX(12,20)
0.318
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
16.288
Sell
MA10
16.568
Sell
MA20
16.288
Sell
MA50
15.810
Sell
MA100
14.278
Buy
MA200
12.069
Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Healthcare Equipment & Supplies industry's average of 6.42. The latest institutional shareholding proportion is 29.46%, representing a quarter-over-quarter decrease of 24.18%. The largest institutional shareholder is James Simons, holding a total of 283.86K shares, representing 1.49% of shares outstanding, with 14.76% decrease in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

No Data

Shareholder Activity

Name
Shares Held
Chg %
Valor Equity Partners
2.10M
--
Masters Capital Management, L.L.C.
1.00M
--
Phoenix Financial Ltd
697.26K
+190.09%
Acadian Asset Management LLC
334.27K
-0.69%
Essex Investment Management Company, LLC
300.94K
-0.73%
Renaissance Technologies LLC
Star Investors
283.86K
-4.83%
Shulkin (Jonathan K.)
268.25K
--
Gracias (Antonio J)
243.50K
--
ARK Investment Management LLC
Star Investors
199.83K
+6.11%
Two Sigma Investments, LP
172.60K
+1.07%
1
2

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.11, which is lower than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.23. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Score

Industry at a Glance

Previous score
4.11
Change
0
Beta vs S&P 500 index
1.24
VaR
+5.33%
240-Day Maximum Drawdown
+32.24%
240-Day Volatility
+57.36%

Return

Best Daily Return
60 days
+14.41%
120 days
+14.41%
5 years
+19.27%
Worst Daily Return
60 days
-4.91%
120 days
-4.91%
5 years
-31.56%
Sharpe Ratio
60 days
+1.90
120 days
+2.25
5 years
+0.53

Risk Assessment

Maximum Drawdown
240 days
+32.24%
3 years
+40.89%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+1.81
3 years
+5.10
5 years
+0.19
Skewness
240 days
+1.00
3 years
+0.52
5 years
-0.16

Volatility

Realised Volatility
240 days
+57.36%
5 years
--
Standardised True Range
240 days
+3.60%
5 years
+2.53%
Downside Risk-Adjusted Return
120 days
+495.41%
240 days
+495.41%
Maximum Daily Upside Volatility
60 days
+44.84%
Maximum Daily Downside Volatility
60 days
+35.81%

Liquidity

Average Turnover Rate
60 days
+0.17%
120 days
+0.14%
5 years
--
Turnover Deviation
20 days
-9.76%
60 days
-33.96%
120 days
-46.97%

Peer Comparison

Healthcare Equipment & Supplies
Brainsway Ltd
Brainsway Ltd
BWAY
6.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Castle Biosciences Inc
Castle Biosciences Inc
CSTL
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
TCMD
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
STERIS plc
STERIS plc
STE
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI